Skip to main content

Table 5 Logistic regression analysis and inverse probability of treatment weighting-adjusted analysis for irAEs in all patients

From: Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study

 

Without IPTW

With IPTW

Univariate analysis

Multivariate analysis

 

OR

95% CI

P value

OR

95% CI

P value

OR

95% CI

P value

Age (≤ 70y vs. > 70 y)

3.77

1.82–8.20

 < 0.01

5.40

2.27–13.90

 < 0.01

   

Sex (Male vs. Female)

0.78

0.37–1.62

0.50

0.93

0.39–2.25

0.87

   

Smoking histology (Never vs. Past/Current)

3.04

0.90–11.96

0.09

3.62

0.87–17.52

0.09

   

Performance status (0–1 vs. ≥ 2)

0.61

0.24–1.56

0.30

1.18

0.87–17.52

0.78

   

Histology (Non-SQ vs. SQ)

1.11

0.51–2.45

0.80

0.92

0.38–2.25

0.85

   

PD-L1 TPS (≥ 50% vs. < 50% or Unknown)

1.20

0.61–2.35

0.60

1.28

0.50–3.27

0.65

   

Postoperative recurrence (No vs. Yes)

0.81

0.40–1.67

0.57

0.79

0.34–1.82

0.58

   

Treatment regimen (Combination therapy vs. Monotherapy)

0.72

0.37–1.38

0.32

0.41

0.14–1.14

0.09

0.56

0.34–0.91

0.019

  1. Abbreviations: IPTW Inverse probability of treatment weighting, OR Odds ratio, CI Confidence interval, SQ Squamous cell carcinoma, PD-L1 TPS Programmed cell death 1-ligand 1 tumor proportion score, irAE immune-related adverse